Sorafenib-associated multivessel coronary artery vasospasm

Herz

Volumn 36, Issue 4, 2011, Pages 348-351

  Naib, T ^a   Steingart, R M ^a   Chen, C L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Coronary spasm; Hypertension; Sorafenib; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOPOIETIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; GEMCITABINE; GLYCERYL TRINITRATE; HEPARIN; ORAL ANTIDIABETIC AGENT; OXALIPLATIN; SORAFENIB; TROPONIN;

ABDOMINAL DISCOMFORT; ADULT; ANGIOCARDIOGRAPHY; ARTERY LESION; ARTICLE; BACKACHE; BONE METASTASIS; CASE REPORT; CAUSE OF DEATH; CHILL; CLINICAL FEATURE; CORONARY ARTERY SPASM; DIABETES MELLITUS; DISEASE COURSE; DIZZINESS; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; DYSPNEA; HUMAN; HYPERTENSION; HYPOTENSION; INDIGESTION; KIDNEY FAILURE; LIVER CELL CARCINOMA; MALE; MULTIPLE ORGAN FAILURE; PHYSICAL EXAMINATION; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; THORAX PAIN; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CORONARY VASOSPASM; ELECTROCARDIOGRAPHY; HUMANS; MALE; MIDDLE AGED; PYRIDINES;

EID: 79959702678     PISSN: 03409937     EISSN: 16156692     Source Type: Journal    
DOI: 10.1007/s00059-011-3444-5     Document Type: Article

References (12)

1. Bayer Pharmaceuticals, pp Nexavar (sorafenib) Prescribing Information. 2010. http://www.nexavarus.com
2. Arima Y, Oshima S, Noda K et al (2009) Sorafenib-induced acute myocardial infarction due to coronary artery spasm. J Cardiol 54:512-515
3. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134 (Pubitemid 46089673)
4. Hennenberg M, Trebicka J, Stark C et al (2009) Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis. Br J Pharmacol 157:258-270
5. Kamba T, McDonald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96:1788-1795 (Pubitemid 46912024)
6. Kandabashi T, Shimokawa H, Miyata K et al (2000) Inhibition of myosin phosphatase by upregulated rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1beta. Circulation 101:1319-1323 (Pubitemid 30158621)
7. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
8. Masumoto A, Mohri M, Shimokawa H et al (2002) Suppression of coronary artery spasm by the Rhokinase inhibitor fasudil in patients with vasospastic angina. Circulation 105:1545-1547 (Pubitemid 34297629)
9. Orphanos GS, Ioannidis GN, Ardavanis AG (2009) Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol 48:964-970
10. Porto I, Leo A, Miele L et al (2010) A case of variant angina in a patient under chronic treatment with sorafenib. Nat Rev Clin Oncol 7:476-480
11. Schmidinger M, Zielinski CC, Vogl UM et al (2008) Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26:5204-5212
12. Siu LL, Awada A, Takimoto CH et al (2006) Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 12:144-151 (Pubitemid 43166188)